Fluvastatin ( DrugBank: Fluvastatin )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
79家族性高コレステロール血症(ホモ接合体)1
218アルポート症候群1
222一次性ネフローゼ症候群1

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 145 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510715
(ClinicalTrials.gov)
August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

218. アルポート症候群


臨床試験数 : 30 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00309257
(ClinicalTrials.gov)
January 200430/3/2006Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNULLCompleted15 Years70 YearsBoth9Phase 2Italy

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TQR-12002602
2009-10-092012-10-16The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change NephropathyThe Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy Minimal change nephrotic syndrome in childrenTreatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day;Treatment center of kidney disease, 281th hospital of PLANULLCompleted412BothTreatment:30;Control:30;I (Phase 1 study)China